thalidomide has been researched along with oprozomib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Appel, A | 1 |
| Moreau, P; Rajkumar, SV | 1 |
| Berenson, JR; Chen, H; Gillespie, A; Li, M; Sanchez, E; Tang, G; Wang, CS | 1 |
| Berdeja, JG; Berenson, JR; Chang, YL; Klippel, Z; Lyons, RM; Niesvizky, R; Rifkin, RM; Shah, J; Stadtmauer, EA; Usmani, S | 1 |
1 review(s) available for thalidomide and oprozomib
| Article | Year |
|---|---|
Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Male; Mice; Mice, SCID; Multiple Myeloma; Neovascularization, Pathologic; Oligopeptides; Thalidomide; Xenograft Model Antitumor Assays | 2017 |
4 other study(ies) available for thalidomide and oprozomib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
Multiple myeloma--translation of trial results into reality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclic N-Oxides; Drug Approval; Drug Discovery; Glycine; Humans; Indolizines; Lactones; Lenalidomide; Multiple Myeloma; Oligopeptides; Practice Guidelines as Topic; Pyridinium Compounds; Pyrroles; Thalidomide | 2016 |
Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Research Design; Retreatment; Thalidomide | 2019 |